atezolizumab,carboplatin,etoposide,tiragolumab
roche
['sclc', 'lcsm,(-blcsm)', 'skyscraper-02', 'skyscraper,2 ', 'lung', 'tiragolumab', 'atezo']
#asco22 day 3: #lungcancer highlights 1/4 sclc:
#skyscraper-02 rct of carbo/etoposide/atezo +/- tiragolumab anti-tigit in es-sclc
n= 490 basically a negative trial:
no diff in pfs/os- os 13.1 vs 12.9mos
no excess toxicity #lcsm 
Associate Director Community Outreach- Thoracic Oncology-University of Miami @SylvesterCancer , Boricua en la Luna, Tweets are my own. (she/her)